Virpax Pharmaceuticals shares are trading higher after Maxim Group upgraded the stock from Hold to Buy and announced a $3 price target.
Portfolio Pulse from Benzinga Newsdesk
Virpax Pharmaceuticals shares are trading higher after Maxim Group upgraded the stock from Hold to Buy and announced a $3 price target.
July 19, 2024 | 3:47 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Virpax Pharmaceuticals shares are trading higher following an upgrade from Maxim Group, which raised the stock rating from Hold to Buy and set a $3 price target.
The upgrade from Maxim Group and the new price target of $3 are likely to boost investor confidence and drive the stock price higher in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100